当前位置：首页 > 文献互助 > 互助详情

One-year remission of therapy-resistant SLE after a single course with the bispecific CD3: BCMA antibody teclistamab, but induction of a non-infectious Crohn’s-like inflammatory bowel disease复制

用户2zEEZfq5qtzA 1小时前 15 10 已关闭

DOI: 10.1016/j.ard.2025.05.007复制

文献链接: https://linkinghub.elsevier.com/retrieve/pii/S0003496725009641复制

其他信息:

出版社: Elsevier BV
作者: Hanns-Martin Lorenz; Wolfgang Merkt; Juliane Brandt; Thomas Giese; Tarik Exner; Norbert Blank; Margarida Souto-Carneiro; Annika Gauss; Marc S. Raab

上一篇：Wnt signaling pathways in biology and disease: mechanisms and therapeutic advances

下一篇：Up-conversion phosphor LaCaGaO4: Er3+/Yb3+ for the optical temperature sensing and anti-counterfeiting

互助时间线

2025-12-04 15:31:49 [关闭求助]

楼主用户2zEEZfq5qtzA关闭了求助

2025-12-04 15:05:55 [发起求助]

最新发布的求助

Exceptional mechanical robust and self-healable rosin-based elastomer through high steric hindrance rigid structures 4分钟前
Lanthanide Ions Doped CsPbBr3 Halides for HTM‐Free 10.14%‐Efficiency Inorganic Perovskite Solar Cell with an Ultrahigh Open‐Circuit Voltage of 1.594 V 29分钟前
Ambient blade-coated perovskite solar cells with high reverse bias stability enabled by polymeric hole transporter design 32分钟前
Pluripotent stem-cell-derived therapies in clinical trial: A 2025 update 44分钟前
Novel antennae for the sensitization of near infrared luminescent lanthanide cations 1小时前
Sputtered Indium‐Zinc Oxide for Buffer Layer Free Semitransparent Perovskite Photovoltaic Devices in Perovskite/Silicon 4T‐Tandem Solar Cells 1小时前
Up-conversion phosphor LaCaGaO4: Er3+/Yb3+ for the optical temperature sensing and anti-counterfeiting 1小时前
One-year remission of therapy-resistant SLE after a single course with the bispecific CD3: BCMA antibody teclistamab, but induction of a non-infectious Crohn’s-like inflammatory bowel disease 1小时前
Wnt signaling pathways in biology and disease: mechanisms and therapeutic advances 1小时前
WNT–β-catenin signalling in hepatocellular carcinoma: from bench to clinical trials 1小时前
Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic Review and Meta-Analysis 2小时前
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study 3小时前

wispass工作室 Copyright © 蜀ICP备2024051606号-2 www.wispass.com